The Horizon Kinetics Medical ETF (the “Fund”) seeks long-term growth of capital. The Fund is an actively-managed exchange-traded fund (“ETF”) that will invest primarily in patented first line pharmaceuticals and biologics as these products tend to have high profit margins and significant barriers to entry. The Fund employs a long-term perspective, seeking to capture returns of both intrinsic valuation realization and scientific discovery.
Data as of: 02/14/2025
-
Ticker
MEDX
-
CUSIP
53656G5633
-
ISIN
US53656G5633
-
Fund Type
Active Equity ETF
-
Exchange
NASDAQ
-
Inception Date
1/27/2023
-
Expense Ratio
0.85%
-
Typical Number of Holdings
25 to 50
-
Net Assets
$16,510,928
Data as of: 02/18/2025
Daily Holdings
-
% Net Assets
17.18%
-
Name
Eli Lilly & Co
-
Ticker
LLY
-
CUSIP
532457108
-
Shares Held
3,359
-
Market Value
$2,835,903
-
% Net Assets
8.97%
-
Name
AbbVie Inc
-
Ticker
ABBV
-
CUSIP
00287Y109
-
Shares Held
7,678
-
Market Value
$1,480,856
-
% Net Assets
6.13%
-
Name
Novartis AG
-
Ticker
NVS
-
CUSIP
66987V109
-
Shares Held
9,597
-
Market Value
$1,011,812
-
% Net Assets
5.92%
-
Name
Amgen Inc
-
Ticker
AMGN
-
CUSIP
031162100
-
Shares Held
3,359
-
Market Value
$978,006
-
% Net Assets
5.80%
-
Name
Bristol-Myers Squibb Co
-
Ticker
BMY
-
CUSIP
110122108
-
Shares Held
17,755
-
Market Value
$956,995
-
% Net Assets
5.56%
-
Name
AstraZeneca PLC
-
Ticker
AZN
-
CUSIP
046353108
-
Shares Held
12,476
-
Market Value
$917,984
-
% Net Assets
5.01%
-
Name
Alkermes PLC
-
Ticker
ALKS
-
CUSIP
G01767105
-
Shares Held
23,033
-
Market Value
$826,654
-
% Net Assets
4.79%
-
Name
Johnson & Johnson
-
Ticker
JNJ
-
CUSIP
478160104
-
Shares Held
5,107
-
Market Value
$791,125
-
% Net Assets
4.60%
-
Name
US BANK MMDA - USBGFS 7 06/01/2031
-
Ticker
USBGFS7
-
CUSIP
8AMMF0FT3
-
Shares Held
759,259
-
Market Value
$759,259
-
% Net Assets
4.47%
-
Name
Alnylam Pharmaceuticals Inc
-
Ticker
ALNY
-
CUSIP
02043Q107
-
Shares Held
2,880
-
Market Value
$738,576
-
% Net Assets
4.01%
-
Name
Pfizer Inc
-
Ticker
PFE
-
CUSIP
717081103
-
Shares Held
25,912
-
Market Value
$661,533
-
% Net Assets
3.38%
-
Name
Merck & Co Inc
-
Ticker
MRK
-
CUSIP
58933Y105
-
Shares Held
6,718
-
Market Value
$557,661
-
% Net Assets
3.18%
-
Name
CRISPR Therapeutics AG
-
Ticker
CRSP
-
CUSIP
H17182108
-
Shares Held
10,557
-
Market Value
$524,894
-
% Net Assets
2.94%
-
Name
Regeneron Pharmaceuticals Inc
-
Ticker
REGN
-
CUSIP
75886F107
-
Shares Held
720
-
Market Value
$484,992
-
% Net Assets
2.59%
-
Name
Biogen Inc
-
Ticker
BIIB
-
CUSIP
09062X103
-
Shares Held
3,119
-
Market Value
$428,332
-
% Net Assets
2.47%
-
Name
GSK PLC
-
Ticker
GSK
-
CUSIP
37733W204
-
Shares Held
11,265
-
Market Value
$407,455
-
% Net Assets
2.35%
-
Name
Ionis Pharmaceuticals Inc
-
Ticker
IONS
-
CUSIP
462222100
-
Shares Held
12,476
-
Market Value
$387,255
-
% Net Assets
1.88%
-
Name
Beam Therapeutics Inc
-
Ticker
BEAM
-
CUSIP
07373V105
-
Shares Held
9,597
-
Market Value
$310,943
-
% Net Assets
1.23%
-
Name
Replimune Group Inc
-
Ticker
REPL
-
CUSIP
76029N106
-
Shares Held
14,396
-
Market Value
$202,984
-
% Net Assets
1.09%
-
Name
Bicycle Therapeutics PLC
-
Ticker
BCYC
-
CUSIP
088786108
-
Shares Held
14,396
-
Market Value
$180,670
-
% Net Assets
0.93%
-
Name
Intellia Therapeutics Inc
-
Ticker
NTLA
-
CUSIP
45826J105
-
Shares Held
14,396
-
Market Value
$154,037
-
% Net Assets
0.87%
-
Name
Lantern Pharma Inc
-
Ticker
LTRN
-
CUSIP
51654W101
-
Shares Held
28,791
-
Market Value
$144,243
-
% Net Assets
0.83%
-
Name
Haleon PLC
-
Ticker
HLN
-
CUSIP
405552100
-
Shares Held
14,082
-
Market Value
$136,736
-
% Net Assets
0.69%
-
Name
Vanda Pharmaceuticals Inc
-
Ticker
VNDA
-
CUSIP
921659108
-
Shares Held
25,912
-
Market Value
$114,531
-
% Net Assets
0.58%
-
Name
Sandoz Group AG
-
Ticker
SDZNY
-
CUSIP
799926100
-
Shares Held
1,920
-
Market Value
$95,386
-
% Net Assets
0.54%
-
Name
GE HealthCare Technologies Inc
-
Ticker
GEHC
-
CUSIP
36266G107
-
Shares Held
960
-
Market Value
$88,522
-
% Net Assets
0.46%
-
Name
Galectin Therapeutics Inc
-
Ticker
GALT
-
CUSIP
363225202
-
Shares Held
53,742
-
Market Value
$75,776
-
% Net Assets
0.27%
-
Name
2seventy bio Inc
-
Ticker
TSVT
-
CUSIP
901384107
-
Shares Held
17,275
-
Market Value
$43,879
-
% Net Assets
0.26%
-
Name
Editas Medicine Inc
-
Ticker
EDIT
-
CUSIP
28106W103
-
Shares Held
31,670
-
Market Value
$43,705
-
% Net Assets
0.25%
-
Name
Cash & Other
-
Ticker
Cash&Other
-
CUSIP
Cash&Other
-
Shares Held
41,579
-
Market Value
$41,579
-
% Net Assets
0.24%
-
Name
Allogene Therapeutics Inc
-
Ticker
ALLO
-
CUSIP
019770106
-
Shares Held
19,194
-
Market Value
$39,156
-
% Net Assets
0.23%
-
Name
Viatris Inc
-
Ticker
VTRS
-
CUSIP
92556V106
-
Shares Held
3,572
-
Market Value
$38,578
-
% Net Assets
0.13%
-
Name
Pacific Biosciences of California Inc
-
Ticker
PACB
-
CUSIP
69404D108
-
Shares Held
11,517
-
Market Value
$21,306
-
% Net Assets
0.08%
-
Name
Bluebird Bio Inc
-
Ticker
BLUE
-
CUSIP
09609G209
-
Shares Held
1,822
-
Market Value
$13,246
-
% Net Assets
0.06%
-
Name
Mural Oncology PLC
-
Ticker
MURA
-
CUSIP
G63365103
-
Shares Held
2,304
-
Market Value
$9,884
-
% Net Assets
0.04%
-
Name
Salarius Pharmaceuticals Inc
-
Ticker
SLRX
-
CUSIP
79400X404
-
Shares Held
3,886
-
Market Value
$6,295
-
% Net Assets
0.00%
-
Name
Pathos AI Inc
-
Ticker
2368714D
-
CUSIP
BBG01L7QKRJ5
-
Shares Held
23,992
-
Market Value
$0
Data as of: 02/18/2025
Daily Holdings
-
% Net Assets
Name
Ticker
CUSIP
Shares Held
Market Value
-
17.18%
Eli Lilly & Co
LLY
532457108
3,359
$2,835,903
-
8.97%
AbbVie Inc
ABBV
00287Y109
7,678
$1,480,856
-
6.13%
Novartis AG
NVS
66987V109
9,597
$1,011,812
-
5.92%
Amgen Inc
AMGN
031162100
3,359
$978,006
-
5.80%
Bristol-Myers Squibb Co
BMY
110122108
17,755
$956,995
-
5.56%
AstraZeneca PLC
AZN
046353108
12,476
$917,984
-
5.01%
Alkermes PLC
ALKS
G01767105
23,033
$826,654
-
4.79%
Johnson & Johnson
JNJ
478160104
5,107
$791,125
-
4.60%
US BANK MMDA - USBGFS 7 06/01/2031
USBGFS7
8AMMF0FT3
759,259
$759,259
-
4.47%
Alnylam Pharmaceuticals Inc
ALNY
02043Q107
2,880
$738,576
-
4.01%
Pfizer Inc
PFE
717081103
25,912
$661,533
-
3.38%
Merck & Co Inc
MRK
58933Y105
6,718
$557,661
-
3.18%
CRISPR Therapeutics AG
CRSP
H17182108
10,557
$524,894
-
2.94%
Regeneron Pharmaceuticals Inc
REGN
75886F107
720
$484,992
-
2.59%
Biogen Inc
BIIB
09062X103
3,119
$428,332
-
2.47%
GSK PLC
GSK
37733W204
11,265
$407,455
-
2.35%
Ionis Pharmaceuticals Inc
IONS
462222100
12,476
$387,255
-
1.88%
Beam Therapeutics Inc
BEAM
07373V105
9,597
$310,943
-
1.23%
Replimune Group Inc
REPL
76029N106
14,396
$202,984
-
1.09%
Bicycle Therapeutics PLC
BCYC
088786108
14,396
$180,670
-
0.93%
Intellia Therapeutics Inc
NTLA
45826J105
14,396
$154,037
-
0.87%
Lantern Pharma Inc
LTRN
51654W101
28,791
$144,243
-
0.83%
Haleon PLC
HLN
405552100
14,082
$136,736
-
0.69%
Vanda Pharmaceuticals Inc
VNDA
921659108
25,912
$114,531
-
0.58%
Sandoz Group AG
SDZNY
799926100
1,920
$95,386
-
0.54%
GE HealthCare Technologies Inc
GEHC
36266G107
960
$88,522
-
0.46%
Galectin Therapeutics Inc
GALT
363225202
53,742
$75,776
-
0.27%
2seventy bio Inc
TSVT
901384107
17,275
$43,879
-
0.26%
Editas Medicine Inc
EDIT
28106W103
31,670
$43,705
-
0.25%
Cash & Other
Cash&Other
Cash&Other
41,579
$41,579
-
0.24%
Allogene Therapeutics Inc
ALLO
019770106
19,194
$39,156
-
0.23%
Viatris Inc
VTRS
92556V106
3,572
$38,578
-
0.13%
Pacific Biosciences of California Inc
PACB
69404D108
11,517
$21,306
-
0.08%
Bluebird Bio Inc
BLUE
09609G209
1,822
$13,246
-
0.06%
Mural Oncology PLC
MURA
G63365103
2,304
$9,884
-
0.04%
Salarius Pharmaceuticals Inc
SLRX
79400X404
3,886
$6,295
-
0.00%
Pathos AI Inc
2368714D
BBG01L7QKRJ5
23,992
$0
Holdings are subject to change.
Data as of: 02/14/2025
-
Net Asset Value
$27.75
-
NAV Change
$-0.14
-
Median 30 Day Spread
0.34%
-
Market Price
$27.76
-
Market Price Change
$-0.13
-
Premium/Discount
$0.01 | 0.03%
Historical Data
Premium/Discount Range (%)
Date
-
Greatest Premium
0.18% 01/16/2025
-
Greatest Discount
-0.50% 01/27/2025
-
Number of Days At
-
Premium:
9
-
NAV:
3
-
Discount:
19
-
Days Within Percent of NAV
-
Percent of Days +/- 0.5% of NAV:
100%
-
Number of Days +/- 0.5% of NAV:
31
Data as of: 12/31/2024
-
NAV
-
1 Month
-6.11%
-
YTD
-4.73%
-
1 Year
-4.73%
-
3 Year
-2.29%
-
5 Year
2.39%
-
Since Inception Annualized
7.75%
-
Market Value
-
1 Month
-6.43%
-
YTD
-4.69%
-
1 Year
-4.69%
-
3 Year
-2.36%
-
5 Year
2.34%
-
Since Inception Annualized
7.74%
Data as of: 12/31/2024
-
1 Month
YTD
1 Year
3 Year
5 Year
Since Inception Annualized
-
NAV
-6.11%
-4.73%
-4.73%
-2.29%
2.39%
7.75%
-
Market Value
-6.43%
-4.69%
-4.69%
-2.36%
2.34%
7.74%
Latest Distribution History
-
Ex-Dividend Date
Dec 24, 2024
-
Record Date
Dec 24, 2024
-
Payable Date
Dec 26, 2024
-
Income
$0.45705493
-
Short Term Capital Gain
$0.01
-
Long Term Capital Gain
$0.04
-
Return of Capital
$0.00
-
Total
$0.50705493
-
Ex-Dividend Date
Dec 27, 2023
-
Record Date
Dec 28, 2023
-
Payable Date
Dec 29, 2023
-
Income
$0.40437284
-
Short Term Capital Gain
$0.00
-
Long Term Capital Gain
$1.23790
-
Return of Capital
$0.00
-
Total
$1.64227284
Latest Distribution History
-
Ex-Dividend
DateRecord Date
Payable Date
Income
Short Term
Capital GainLong Term
Capital GainReturn of
CapitalTotal
-
Dec 24, 2024
Dec 24, 2024
Dec 26, 2024
$0.45705493
$0.01
$0.04
$0.00
$0.50705493
-
Dec 27, 2023
Dec 28, 2023
Dec 29, 2023
$0.40437284
$0.00
$1.23790
$0.00
$1.64227284
Resources
-
2024 ETF Distributions
View PDF -
MEDX Factsheet
View PDF -
MEDX 2024 Semi-Annual Letter
View PDF -
MEDX Presentation
View PDF -
MEDX 3/31/2024 Quarterly Schedule of Portfolio Holdings
View PDF -
MEDX Summary Prospectus
View PDF -
MEDX Prospectus
View PDF -
MEDX Statement of Additional Information
View PDF -
MEDX Semi-Annual Shareholder Report June 30, 2024
View PDF -
Semi-Annual Financial Statements and Additional Information June 30, 2024 (Unaudited)
View PDF -
2023 ETF Distribution
View PDF -
2023 Annual Report
View PDF -
Form N-PX Voting Record
View
-
2024 ETF Distributions
View PDF -
MEDX Factsheet
View PDF -
MEDX 2024 Semi-Annual Letter
View PDF -
MEDX Presentation
View PDF -
MEDX 3/31/2024 Quarterly Schedule of Portfolio Holdings
View PDF -
MEDX Summary Prospectus
View PDF -
MEDX Prospectus
View PDF -
MEDX Statement of Additional Information
View PDF -
MEDX Semi-Annual Shareholder Report June 30, 2024
View PDF -
Semi-Annual Financial Statements and Additional Information June 30, 2024 (Unaudited)
View PDF -
2023 ETF Distribution
View PDF -
2023 Annual Report
View PDF -
Form N-PX Voting Record
View
IMPORTANT RISK DISCLOSURES
Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory prospectus and summary prospectus by contacting 646-495-7333. Read it carefully before investing.
The Horizon Kinetics Medical ETF (Symbol: MEDX) is an exchange traded fund managed by Horizon Kinetics Asset Management LLC (“HKAM”).
Please visit horizonkineticsetf.com/medx to access the Funds’ standardized performance and expense ratio. The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For performance current to most recent month end please call 646-495-7333.
Since Inception returns are as of September 30, 1999. Effective January 27, 2023, the Medical Fund Fund (“Predecessor Fund”) was reorganized into the Horizon Kinetics Medical ETF and first listed on the exchange on [exchange listing date for the ETF], The returns shown for periods ending on or prior to January 27, 2023 are those of the predecessor fund, a 1940 Act mutual fund. Returns of the ETF will be different from the returns of the predecessor fund as they have different expenses. Market returns as of January 27, 2023 and going forward are based on the closing price on the listed exchange at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Prior to this date, all returns are based on the Predecessor’s fund 4:00 PM ET NAV.
Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund’s investments in securities linked to real assets involve significant risks, including financial, operating, and competitive risks. Investments in securities linked to real assets expose the Fund to potentially adverse macroeconomic conditions, such as a rise in interest rates or a downturn in the economy in which the asset is located.
Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.
Equity Market Risk. The equity securities held in the Fund’s portfolio may experience sudden, unpredictable drops in value or long
periods of decline in value.
Emerging Markets Risk. The Fund may invest in companies organized in emerging market nations. Investments in securities and instruments traded in developing or emerging markets, or that provide exposure to such securities or markets, can involve additional risks relating to political, economic, currency fluctuations or regulatory conditions not associated with investments in U.S. securities and instruments or investments in more developed international markets.
Non-Diversification Risk. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund.
New Fund Risk. The Fund is a recently organized investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision.
Associated Risks of Investing in the Medical Industry. Medical and pharmaceutical related companies in general are subject to the rate of change in technology, which is generally higher than that of other industries.
Below Investment Grade Bonds Risk. The Fund’s investments in below investment grade bonds are subject to a greater risk of loss of income and principal than higher grade debt securities.
Concentration Risk. The Fund expects to concentrate (i.e., invest more than 25% of its net assets) its investments in a limited number of issuers
Derivatives Risk. Put and call options are referred to as “derivative” instruments since their values are based on, or derived from, an underlying reference asset, such as an index.
Liquidity Risk. Liquidity risk refers to the possibility that the Fund may not be able to sell or buy a security or close out an investment contract at a favorable price or time.
Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the Options Risk. The prices of options may change rapidly over time and do not necessarily move in tandem with the price of the underlying securities.
HKAM does not provide tax or legal advice, all investors are encouraged to consult their tax and legal advisors regarding an investment in the Fund. You may obtain additional information about HKAM at our website at www.horizonkinetics.com.
No part of this material may be copied, photocopied, or duplicated in any form, by any means, or redistributed without the express written consent of HKAM.
The Horizon Kinetics Medical ETF (MEDX) is distributed by Foreside Fund Services, LLC (“Foreside”). Foreside is not affiliated with MEDX or Horizon Kinetics LLC or its subsidiaries.